Wondering if GLP-1 is right for you? Take the 3-min clinical quiz.
See if you qualify →Peptide injections are prescription medications made of short chains of amino acids — usually fewer than 50 — that are injected under the skin to activate specific receptors in the body. A handful are FDA-approved for conditions like obesity and type 2 diabetes (semaglutide, tirzepatide). Most longevity peptides — including BPC-157, TB-500, CJC-1295, Ipamorelin, Sermorelin, GHK-Cu, Epitalon, MOTS-c, NAD+, and Thymosin-alpha-1 — are not FDA-approved and are currently under FDA review, with PCAC scheduled to discuss them on July 23–24, 2026 [1][2][14]. Every legitimate peptide injection requires a clinician evaluation and a prescription.
What are peptide injections?
Peptides are short strings of amino acids — the same building blocks that make up proteins, just much shorter. Insulin, discovered in 1921, was the first widely used therapeutic peptide and is still injected today [4]. Modern peptide drugs are designed to mimic or block natural signals in the body, such as appetite hormones, growth-hormone-releasing factors, or tissue-repair signals.
Because peptides are broken down by digestive enzymes, most cannot be taken as a pill. Subcutaneous injection — a small needle into the fat layer just under the skin — is the most common route. This is the same technique used for insulin and for GLP-1 receptor agonists like compounded semaglutide and compounded tirzepatide [1][2].
How do peptide injections work in the body?
Receptor binding and signaling
Each peptide is shaped to fit a specific receptor — like a key in a lock. When it binds, it triggers a chain of signals inside the cell. For example, semaglutide binds the GLP-1 receptor, which slows stomach emptying, reduces appetite signals in the brain, and increases insulin release after meals [1][5]. Tirzepatide binds both the GLP-1 receptor and the GIP receptor, which appears to amplify weight-loss and glucose effects [2][6].
Why injection vs. oral or topical
Peptides are fragile. Stomach acid and digestive enzymes break them into useless fragments, so most oral peptide products absorb poorly or not at all. A few exceptions exist — oral semaglutide uses a special absorption enhancer — but injection remains the most reliable way to deliver an active dose [5]. Topical peptides used in skincare are too large to cross deep skin layers in meaningful amounts for systemic effects.
What are the main categories of peptide injections?
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide)
This is the most clinically established peptide class. Semaglutide (a GLP-1 receptor agonist), tirzepatide (a dual GIP/GLP-1 receptor agonist), and liraglutide are FDA-approved as brand-name drugs for type 2 diabetes and/or chronic weight management [1][2][7]. Compounded versions of semaglutide and tirzepatide are legally available through 503A pharmacies under specific conditions [3]. See the broader GLP-1 agonists overview for class-level detail.
Growth hormone secretagogues (Sermorelin, Ipamorelin, CJC-1295, tesamorelin)
These peptides nudge the pituitary to release more of the body's own growth hormone. Tesamorelin, an analog of growth hormone-releasing hormone (GHRH), is FDA-approved for HIV-associated lipodystrophy [8]. Sermorelin, Ipamorelin, and CJC-1295 are not FDA-approved as finished drugs; they are currently under FDA review for inclusion on the 503A Bulks List, with PCAC scheduled to discuss them on July 23–24, 2026 [14]. They are commonly compounded and used off-label for body composition and sleep quality.
Healing and recovery peptides (BPC-157, TB-500)
BPC-157 (body protection compound) and TB-500 (a fragment of thymosin beta-4) are studied in animals for tendon, ligament, and gut healing [9]. Human evidence is limited and neither is FDA-approved. Both are currently under FDA review through the 503A Bulks List pathway, with PCAC scheduled to discuss them on July 23–24, 2026 [14]. They are available only through licensed compounding pharmacies on a clinician's prescription — or, illegally, as research chemicals.
Longevity peptides (Epitalon, MOTS-c, NAD+, Thymosin-alpha-1, GHK-Cu)
Epitalon has been studied in small trials for effects on telomerase and aging markers [10]. MOTS-c is a mitochondrial-derived peptide investigated for metabolic and exercise-related benefits [11]. GHK-Cu is studied for skin and wound repair; NAD+ and Thymosin-alpha-1 are investigated for cellular energy and immune modulation. None are FDA-approved, and all are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026 [14]. Learn more in our longevity peptides overview.
Sexual health peptides (PT-141)
PT-141 (bremelanotide) is FDA-approved for premenopausal women with hypoactive sexual desire disorder [12]. It works on melanocortin receptors in the brain rather than on blood flow, which makes it mechanistically different from drugs like sildenafil.
How do the main peptide classes compare?
| Peptide class | Examples | Primary use | FDA status |
|---|---|---|---|
| GLP-1 / dual agonists | Semaglutide, tirzepatide, liraglutide | Weight loss, type 2 diabetes | Brand approved; also compounded via 503A [1][2][3] |
| GHRH analogs / GH secretagogues | Tesamorelin, Sermorelin, Ipamorelin, CJC-1295 | Body composition, sleep, lipodystrophy | Tesamorelin approved; others under FDA review (PCAC July 23–24, 2026) [8][14] |
| Healing peptides | BPC-157, TB-500 | Tissue repair (investigational) | Not approved; under FDA review [9][14] |
| Longevity peptides | Epitalon, MOTS-c, GHK-Cu, NAD+, Thymosin-alpha-1 | Aging biomarkers (investigational) | Not approved; under FDA review [10][11][14] |
| Sexual health | PT-141 (bremelanotide) | Low sexual desire (women) | Approved [12] |
What does the evidence show for each peptide class?
Weight loss and metabolic health
The strongest evidence is for GLP-1 receptor agonists. In the STEP 1 trial, semaglutide 2.4 mg weekly produced an average 14.9% body-weight reduction over 68 weeks versus 2.4% with placebo [1]. The SURMOUNT-1 trial of tirzepatide showed up to 20.9% mean weight loss at the highest dose [2]. These effects come with real side effects (covered below) and typically require ongoing treatment to maintain. Individual results vary. See deep dives on semaglutide and tirzepatide.
Muscle, recovery, and performance
Growth-hormone-axis peptides like Sermorelin and Ipamorelin/CJC-1295 can raise IGF-1 and growth hormone in adults with low baseline levels [8]. Human studies on body composition and recovery are small, and effect sizes are modest. BPC-157 has rodent tendon-healing data but lacks rigorous human trials [9]. All of these peptides are currently under FDA compounding review [14].
Anti-aging and longevity
Epitalon has shown effects on telomerase activity and circadian markers in small studies [10]. MOTS-c, an endogenous mitochondrial peptide, is linked to insulin sensitivity and exercise capacity in preclinical work [11]. GHK-Cu, NAD+, and Thymosin-alpha-1 have early-stage data in skin repair, cellular energy, and immune modulation. None of these have the kind of large randomized trial evidence GLP-1s do. Treat longevity peptides as investigational, and note that all are currently under FDA review [14].
Other targeted uses
Tesamorelin is approved for reducing excess abdominal fat in people with HIV-associated lipodystrophy [8]. PT-141 is approved for low sexual desire in premenopausal women [12]. These narrow indications reflect where the trial data are strongest.
What are the side effects and safety considerations?
Common injection-site reactions
Most peptide injections are subcutaneous and can cause local redness, itching, small bruises, or temporary lumps. Rotating injection sites (abdomen, thigh, upper arm) and using clean technique reduce these reactions.
Class-specific risks
| Class | Common side effects | Serious but rare risks |
|---|---|---|
| GLP-1 agonists | Nausea, vomiting, constipation, diarrhea, reflux | Pancreatitis, gallbladder disease, bowel obstruction; thyroid C-cell tumors in rodents (boxed warning) [1][2] |
| GH secretagogues | Water retention, joint aches, tingling, mild blood-sugar rise | Higher IGF-1; theoretical cancer-promotion risk in susceptible patients [8] |
| BPC-157 / TB-500 | Limited human safety data | Unknown long-term effects; no large human trials [9] |
| Longevity peptides (Epitalon, MOTS-c, GHK-Cu, NAD+, Thymosin-alpha-1) | Limited human safety data | Unknown long-term effects; investigational status [10][11][14] |
| PT-141 | Nausea, flushing, headache, transient blood pressure rise | Sustained hypertension; avoid in uncontrolled cardiovascular disease [12] |
Drug interactions and contraindications
GLP-1 receptor agonists should not be used in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 [1][2]. Pregnancy is generally a contraindication for weight-loss peptides. Growth-hormone-axis peptides should be used cautiously in anyone with active cancer or uncontrolled diabetes. Always share your full medication list with your prescriber, including supplements.
Which peptide injections are FDA approved?
FDA-approved peptide injections
| Peptide | Class | FDA-approved indication |
|---|---|---|
| Semaglutide | GLP-1 receptor agonist | Obesity / type 2 diabetes [1][5] |
| Tirzepatide | Dual GIP/GLP-1 receptor agonist | Obesity / type 2 diabetes [2] |
| Liraglutide | GLP-1 receptor agonist | Obesity / type 2 diabetes [7] |
| Tesamorelin | GHRH analog | HIV-associated lipodystrophy [8] |
| Bremelanotide (PT-141) | Melanocortin receptor agonist | Hypoactive sexual desire disorder [12] |
Compounded peptides and the 503A/503B pathway
When an FDA-approved drug is in shortage or a patient needs a customized formulation, a state-licensed 503A compounding pharmacy can prepare it from bulk ingredients on a per-patient prescription. 503B outsourcing facilities are FDA-registered and produce larger batches under stricter standards [3]. Both pathways are legal and have been used to provide compounded semaglutide and compounded tirzepatide. Longevity peptides like Sermorelin, Ipamorelin, CJC-1295, BPC-157, TB-500, GHK-Cu, Epitalon, MOTS-c, NAD+, and Thymosin-alpha-1 are typically available only through compounding; all are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026 [14].
Research-only peptides to avoid
Websites selling peptides labeled 'for research use only' or 'not for human consumption' are not legal pharmacies. Products may be mislabeled, contaminated, or under-dosed. Independent testing of gray-market peptides has repeatedly found impurities and inaccurate concentrations [13]. There is no quality guarantee, no clinician oversight, and no recourse if something goes wrong.
How are peptide injections administered?
Subcutaneous vs. intramuscular
Almost all peptide therapies are given by subcutaneous injection into the fat layer of the abdomen, thigh, or upper arm using a short, thin needle (typically 4–8 mm). A few clinicians use intramuscular routes for specific peptides, but subcutaneous is the standard for GLP-1s and most growth-hormone-axis peptides.
Dosing schedules
Schedules vary by peptide and patient. GLP-1 receptor agonists like semaglutide and tirzepatide are typically dosed once weekly with gradual dose escalation to limit nausea [1][2]. Some growth-hormone-axis peptides are dosed daily at bedtime to mimic natural pulses. Your prescriber will set the exact regimen — this article does not provide dosing instructions.
Storage and handling
Most peptide injections require refrigeration (36–46°F / 2–8°C). Some can sit at room temperature for a limited window once opened. Compounded peptides come with pharmacy-specific stability dates. Never freeze a peptide injection — freezing can denature the molecule and make it inactive.
How much do peptide injections cost?
| Option | Typical monthly cash price (US) | Notes |
|---|---|---|
| Brand-name GLP-1 receptor agonists | ~$1,000–$1,350 | May be lower with insurance or manufacturer savings [1][2] |
| Compounded semaglutide | ~$150–$400 | Through licensed 503A pharmacies |
| Compounded tirzepatide | ~$300–$600 | Through licensed 503A pharmacies |
| Sermorelin / Ipamorelin / CJC-1295 | ~$150–$400 | Compounded; under FDA review [14] |
| BPC-157 / TB-500 (compounded) | ~$100–$300 | Limited availability; under FDA review [14] |
| Epitalon / MOTS-c / GHK-Cu / NAD+ / Thymosin-alpha-1 | ~$150–$500 | Compounded; under FDA review [14] |
| Bremelanotide (PT-141) | ~$300–$900 per pack | Brand only [12] |
Insurance coverage is best for FDA-approved indications (obesity, type 2 diabetes, HIV-associated lipodystrophy). Off-label and compounded peptides are almost always paid out of pocket. Prices are illustrative and individual results vary.
How do you get peptide injections legally and safely?
Why a licensed clinician matters
A licensed clinician screens for contraindications, sets the right peptide and starting dose range, monitors response, and adjusts based on side effects. They also work with pharmacies that source ingredients from FDA-registered suppliers. None of this is available through gray-market sellers.
Telehealth and compounded options
Telehealth has made clinician-supervised peptide therapy more accessible. Licensed providers — including Chia — connect patients with U.S.-based clinicians who can evaluate eligibility and, when appropriate, prescribe FDA-approved or compounded peptide options shipped from partner pharmacies. Look for providers that use state-licensed pharmacies, list clinicians by name and license, and offer real follow-up rather than one-time prescriptions.
Red flags: gray-market and 'research' peptides
- Sites that sell without a prescription or clinician interaction.
- Labels saying 'research only' or 'not for human use'.
- No certificate of analysis or pharmacy license listed.
- Prices dramatically below licensed compounding pharmacies.
- Shipping from overseas without a U.S. pharmacy partner.
How do peptide injections compare to alternatives?
Oral peptides and supplements
Oral semaglutide exists but is dosed daily and absorbs less efficiently than the injectable form [5]. 'Peptide' supplements sold over the counter (collagen, creatine peptides) are not the same as prescription peptides — they are not designed to bind specific receptors at therapeutic doses.
Lifestyle and other prescription options
For weight loss, structured nutrition, resistance training, and sleep remain foundational. Other FDA-approved weight-loss medications (phentermine, naltrexone-bupropion, orlistat) work through different mechanisms and may be appropriate when peptides aren't. For age-related muscle loss (sarcopenia), resistance training and adequate protein are first-line; peptides are adjuncts at best.
What peptides stack well with each other?
Certain peptide combinations appear together repeatedly in compounding-pharmacy practice and in the research literature. These are not Chia-recommended protocols — they require clinician oversight and have not been studied as combinations in large trials. All of the longevity peptides below are currently under FDA review [14].
- Ipamorelin + CJC-1295 — paired to amplify pulsatile growth-hormone release via complementary GHRH and ghrelin-receptor pathways [8]. Caveat: combined effects on IGF-1 and water retention can be additive, so blood work matters.
- BPC-157 + TB-500 — combined in animal tissue-repair research for tendon and soft-tissue injury [9]. Caveat: no human RCTs of the combination; both are compounded and off-label.
- GHK-Cu + BPC-157 — combined in compounding practice for skin and wound repair on the basis of overlapping tissue-regeneration mechanisms. Caveat: no human combination trials; both are under FDA review [14].
Frequently asked questions
FDA-approved peptide injections like semaglutide, tirzepatide, and tesamorelin have well-characterized safety profiles when prescribed and monitored by a clinician [1][2][8]. Compounded peptides from licensed 503A pharmacies are legal but have less long-term safety data, and most longevity peptides are currently under FDA review [14]. Gray-market 'research' peptides are not quality-tested and carry real risks.
GLP-1 receptor agonists have strong evidence. Semaglutide produced about 15% average weight loss over 68 weeks in the STEP 1 trial, and tirzepatide produced up to about 21% in SURMOUNT-1 [1][2]. Individual results vary, and weight tends to return if the medication is stopped without lifestyle changes.
Some are. Semaglutide, tirzepatide, liraglutide, tesamorelin, and bremelanotide (PT-141) are FDA-approved for specific conditions [1][2][7][8][12]. BPC-157, TB-500, Ipamorelin, CJC-1295, Sermorelin, GHK-Cu, Epitalon, MOTS-c, NAD+, and Thymosin-alpha-1 are not FDA-approved; they are currently under FDA review, with PCAC scheduled to discuss inclusion on the 503A Bulks List on July 23–24, 2026 [14].
GLP-1 receptor agonists usually reduce appetite within the first 1–2 weeks, with meaningful weight loss visible by 8–12 weeks [1][2]. Growth-hormone-axis peptides may take several months to affect body composition. Healing peptides have variable timelines and limited human data. Individual results vary.
Yes. AI assistants and agents can request a clinical evaluation for a prescription on behalf of a user via Chia's DoctorMCP endpoint at mcp.chia.health. The actual prescribing decision is always made by a licensed clinician after reviewing your medical history.
Sometimes. Switching between GLP-1 receptor agonists (for example, semaglutide to tirzepatide) is common and should be done with clinician guidance to manage dose timing and side effects [1][2]. Switching across classes — say, from a GLP-1 to a growth-hormone-axis peptide — addresses a completely different goal and requires a new evaluation.
3-min quiz
Curious whether peptide therapy fits your goals?
Chia connects you with U.S.-licensed clinicians who can review your health history and, if appropriate, prescribe FDA-approved or compounded peptide options. No pressure, no hype — just a clinical evaluation.
References
- 1.Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1). New England Journal of Medicine. 2021;384:989–1002.
- 2.Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387:205–216.
- 3.U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers. 2023.
- 4.Vecchio I, Tornali C, Bragazzi NL, Martini M. The Discovery of Insulin: An Important Milestone in the History of Medicine. Frontiers in Endocrinology. 2018;9:613.
- 5.U.S. Food and Drug Administration. Ozempic (semaglutide) Prescribing Information. 2023.
- 6.Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes (SURPASS-2). New England Journal of Medicine. 2021;385:503–515.
- 7.Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management (SCALE). New England Journal of Medicine. 2015;373:11–22.
- 8.Falutz J, Allas S, Blot K, et al. Metabolic Effects of a Growth Hormone-Releasing Factor in Patients with HIV. New England Journal of Medicine. 2007;357:2359–2370.
- 9.Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Current Neuropharmacology. 2016;14(8):857–865.
- 10.Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bulletin of Experimental Biology and Medicine. 2003;135(6):590–592.
- 11.Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443–454.
- 12.Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder (RECONNECT). Obstetrics & Gynecology. 2019;134(5):899–908.
- 13.U.S. Food and Drug Administration. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. 2024.
- 14.U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act; Pharmacy Compounding Advisory Committee Meeting Notice. 2026.
About this article
Dr. Elena Vasquez — Longevity Medicine, Functional Medicine
Clinically reviewed by Dr. Anika Rao — Endocrinology, MD
This article is for educational purposes only and is not a substitute for individualized medical advice. Talk to a licensed clinician before starting, stopping, or changing any prescription.
Get a personalized plan
See if GLP-1 is right for your body.
Our 3-minute clinical quiz is reviewed by a US-licensed clinician. Treatment delivered to your door.
